Melanoma, a highly heterogeneous tumor, is comprised of a functionally diverse spectrum of
cell phenotypes and subpopulations, including stromal cells in the tumor microenvironment …

Despite the recent success of MAPK and immune checkpoint inhibitors in advanced
melanoma, intrinsic and acquired resistance mechanisms determine the efficacy of these …

Melanoma is the deadliest form of skin cancer. Although targeted therapies and
immunotherapies have revolutionized the treatment of metastatic melanoma, most patients …

Malignant melanoma is notorious for its inter-and intratumour heterogeneity, based on
transcriptionally distinct melanoma cell phenotypes. It is thought that these distinct …

Cutaneous melanoma (CM) tissue represents a network constituted by cancer cells and
tumor microenvironment (TME). A key feature of CM is the high structural and cellular …

Drug resistance constitutes a major challenge in designing melanoma therapies.
Microenvironment-driven tumor heterogeneity and plasticity play a key role in this …

Immunotherapies blocking negative immune checkpoints are now approved for the
treatment of a growing number of cancers. However, even in metastatic melanoma, where …

Simple Summary Late-stage melanoma is one of the leading causes of death from skin
cancers, as it frequently acquires resistance to standard therapies. Melanoma …

Melanoma cells are notorious for their high plasticity and ability to switch back and forth
between various melanoma cell states, enabling the adaptation to sub-optimal conditions …

Melanoma arises through the accrual of mutations in genes critical for proliferation and
survival. Although melanoma had been traditionally conceptualized as a cell-autonomous …